Lexicon Stock Analysis

LXRX
 Stock
  

USD 2.26  0.12  5.61%   

Lexicon Pharmaceuticals price slide over the last few months may encourage investors to take a closer look at the firm as it is trading at a share price of 2.26 on 299,638 in trading volume. The company directors and management were not very successful in positioning the firm resources to exploit market volatility in November. However, diversifying your holdings with Lexicon Pharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.97. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Lexicon Pharmaceuticals partners.
Additionally, see Correlation Analysis.
  
The Lexicon Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Lexicon Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Lexicon Stock analysis module also helps to analyze the Lexicon Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Lexicon Stock Analysis Notes

About 82.0% of the company shares are owned by institutional investors. The book value of Lexicon Pharmaceuticals was now reported as 0.76. The company recorded a loss per share of 0.61. Lexicon Pharmaceuticals had not issued any dividends in recent years. The entity had 1:7 split on the 21st of May 2015. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceutcl operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people. To find out more about Lexicon Pharmaceuticals contact Lonnel Coats at 281 863 3000 or learn more at https://www.lexpharma.com.

Lexicon Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Lexicon Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Lexicon Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Lexicon Pharmaceuticals generated a negative expected return over the last 90 days
Lexicon Pharmaceuticals has high historical volatility and very poor performance
The company reported the previous year's revenue of 298 K. Net Loss for the year was (87.76 M) with loss before overhead, payroll, taxes, and interest of (54.75 M).
Lexicon Pharmaceuticals currently holds about 61.97 M in cash with (87.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34.
Over 82.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: X4 Pharmaceuticals pulls together some positive data results after a rocky year - Endpoints News

Lexicon Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Lexicon Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lexicon Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of March 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End9th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Lexicon Largest EPS Surprises

Earnings surprises can significantly impact Lexicon Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-03
2021-09-30-0.18-0.160.0211 
2021-07-30
2021-06-30-0.16-0.130.0318 
2016-05-03
2016-03-31-0.3-0.34-0.0413 
View All Earnings Estimates

Lexicon Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Lexicon Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Lexicon Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Lexicon Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of September 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
9th of August 2022
Unclassified Corporate Event
View
2nd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
1st of August 2022
Unclassified Corporate Event
View
29th of July 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
30th of June 2022
Other Events
View
25th of May 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Material Modifications to Rights of Security Holders
View
5th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Lexicon Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Lexicon Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lexicon Pharmaceuticals backward and forwards among themselves. Lexicon Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Lexicon Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares12.7 K30 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares12.7 K24 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares12.7 K27 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares12.7 K50 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.2 KK
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.2 K17 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.2 K13 K
Note, although Lexicon Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Lexicon Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 426.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lexicon Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Lexicon Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Lexicon Profitablity

Lexicon Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Lexicon Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Lexicon Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Lexicon Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Lexicon Pharmaceuticals' profitability requires more research than a typical breakdown of Lexicon Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(61.85) (66.73) 
Return on Average Assets(51.52) (52.87) 
Return on Average Equity(65.01) (70.14) 
Return on Invested Capital(5.88) (6.04) 
Return on Sales(291.80) (299.48) 

Management Efficiency

The entity has return on total asset (ROA) of (0.329) % which means that it has lost $0.329 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.6918) %, meaning that it created substantial loss on money invested by shareholders. Lexicon Pharmaceuticals management efficiency ratios could be used to measure how well lexicon pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -66.73 in 2022. Return on Average Assets is likely to drop to -52.87 in 2022. Lexicon Pharmaceuticals Tangible Asset Value is fairly stable at the moment as compared to the past year. Lexicon Pharmaceuticals reported Tangible Asset Value of 92.37 Million in 2021
Last ReportedProjected for 2022
Book Value per Share 0.78  0.80 
Enterprise Value over EBIT(6.00) (6.16) 
Enterprise Value over EBITDA(5.84) (6.00) 
Price to Book Value 5.16  5.57 
Tangible Assets Book Value per Share 0.63  0.65 
Enterprise Value506.2 M619.8 M
Tangible Asset Value92.4 M94.8 M

Technical Drivers

As of the 4th of December, Lexicon Pharmaceuticals secures the mean deviation of 3.13, and Risk Adjusted Performance of (0.07). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lexicon Pharmaceuticals, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Lexicon Pharmaceuticals, which can be compared to its peers in the industry. Please verify Lexicon Pharmaceuticals jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Lexicon Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 2.26 per share. Please also check out Lexicon Pharmaceuticals total risk alpha, which is currently at (0.49) to check the company can sustain itself at a future point.

Lexicon Pharmaceuticals Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Lexicon Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Lexicon Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Lexicon Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexicon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexicon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lexicon Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Invus Us Partners Llc over three months ago via Macroaxis 
Lexicon Pharmaceutcl exotic insider transaction detected
Judith Swain over six months ago via Macroaxis 
Acquisition by Judith Swain of 9302 shares of Lexicon Pharmaceutcl subject to Rule 16b-3
Judith Swain over six months ago via Macroaxis 
Exercise or conversion by Judith Swain of 4024 shares of Lexicon Pharmaceutcl subject to Rule 16b-3
Kiernan Seth over six months ago via Macroaxis 
Exercise or conversion by Kiernan Seth of 5287 shares of Lexicon Pharmaceutcl subject to Rule 16b-3
Mcdermott Wendy over six months ago via Macroaxis 
Acquisition by Mcdermott Wendy of 56830 shares of Lexicon Pharmaceutcl subject to Rule 16b-3
Jeffrey Wade over six months ago via Macroaxis 
Bona fide gift to Jeffrey Wade of 4500 shares of Lexicon Pharmaceutcl subject to Section 16
Christopher Sobecki over six months ago via Macroaxis 
Bona fide gift to Christopher Sobecki of 5700 shares of Lexicon Pharmaceutcl subject to Section 16
Mcdermott Wendy over six months ago via Macroaxis 
Acquisition by Mcdermott Wendy of 85185 shares of Lexicon Pharmaceutcl subject to Rule 16b-3
Kiernan Seth over a year ago via Macroaxis 
Lexicon Pharmaceutcl exotic insider transaction detected
Kasslertaub Kenneth B over a year ago via Macroaxis 
Lexicon Pharmaceutcl exotic insider transaction detected
Alexander Kristen over a year ago via Macroaxis 
Lexicon Pharmaceutcl exotic insider transaction detected
Granowitz Craig B over a year ago via Macroaxis 
Acquisition by Granowitz Craig B of 250000 shares of Lexicon Pharmaceutcl subject to Rule 16b-3

Lexicon Pharmaceuticals Predictive Daily Indicators

Lexicon Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lexicon Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Lexicon Pharmaceuticals Forecast Models

Lexicon Pharmaceuticals time-series forecasting models is one of many Lexicon Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lexicon Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Lexicon Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lexicon Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lexicon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Lexicon Pharmaceuticals. By using and applying Lexicon Stock analysis, traders can create a robust methodology for identifying Lexicon entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 39.53  42.65 
EBITDA Margin 40.96  44.19 
Gross Margin 105.75  111.37 
Profit Margin 36.36  39.23 

Current Lexicon Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lexicon analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lexicon analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
6.0Hold1Odds
Lexicon Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Lexicon analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Lexicon stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Lexicon Pharmaceuticals, talking to its executives and customers, or listening to Lexicon conference calls.
Lexicon Analyst Advice Details

Lexicon Stock Analysis Indicators

Lexicon Pharmaceuticals stock analysis indicators help investors evaluate how Lexicon Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lexicon Pharmaceuticals shares will generate the highest return on investment. By understating and applying Lexicon Pharmaceuticals stock analysis, traders can identify Lexicon Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow126263000.00
Total Stockholder Equity-1487776000.00
Country NameUSA
Capital Lease Obligations2279000.00
Property Plant And Equipment Net1176000.00
Retained Earnings-1487776000.00
Cash And Short Term Investments64065000.00
Retained Earnings Total Equity-1487776000.00
Cash64065000.00
50 Day M A2.2028
Net Interest Income-668000.00
Total Current Liabilities22124000.00
Common Stock Total Equity150000.00
Interest Expense802000.00
Logo U R LimglogosUSLXRX.png
Common Stock Shares Outstanding145820000.00
Total Cashflows From Investing Activities2110000.00
Quarterly Earnings Growth Y O Y-0.634
CodeLXRX
Accounts Payable9152000.00
Net Debt-64065000.00
Currency CodeUSD
Other Operating Expenses87388000.00
Non Current Assets Total47988000.00
Liabilities And Stockholders Equity-1464462000.00
Non Currrent Assets Other-20409000.00
Additionally, see Correlation Analysis. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for analysis

When running Lexicon Pharmaceuticals price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
(0.63) 
Market Capitalization
426.5 M
Quarterly Revenue Growth YOY
0.7
Return On Assets
(0.33) 
Return On Equity
(0.69) 
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Lexicon Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.